How long does Tirzepatide stay in your system?
Tirzepatide has a published half-life of approximately 5 days. By the standard pharmacology rule of thumb, a drug is about 97% eliminated after roughly five half-lives, which here works out to about 25 days (3.6 weeks). The Zepbound label, for the same molecule in patients with overweight or obesity, states approximately 5 to 6 days instead.
Source: Mounjaro label, DailyMed · FDA label · measured: subcutaneous · dataset reviewed September 23, 2026
What is the half-life of Tirzepatide?
The Mounjaro prescribing information gives tirzepatide a half-life of approximately 5 days after subcutaneous injection. Tirzepatide is a single peptide that activates two receptors, GIP and GLP-1, and its backbone is modelled more closely on the hormone GIP than on GLP-1.
Neither natural hormone survives long in the blood. Tirzepatide's days-long half-life comes from a fatty-acid side chain that binds serum albumin, the same broad strategy used in semaglutide. The bound drug is protected from breakdown and released gradually, so the decline in concentration is measured in days.
How much Tirzepatide is left after each half-life?
Each half-life removes half of whatever is left, so the percentages are pure arithmetic and the same for any compound; only the clock changes. For Tirzepatide, one half-life is 5 days. The rows below run that forward for a single amount with nothing added.
| Half-lives elapsed | Time elapsed | Remaining | Cleared |
|---|---|---|---|
| 1 | 5 days | 50% | 50% |
| 2 | 10 days | 25% | 75% |
| 3 | 15 days (2.1 weeks) | 12.5% | 87.5% |
| 4 | 20 days (2.9 weeks) | 6.25% | 93.75% |
| 5 | 25 days (3.6 weeks) | 3.13% | 96.88% |
| 6 | 30 days (4.3 weeks) | 1.56% | 98.44% |
| 7 | 35 days (5 weeks) | 0.78% | 99.22% |
Why do the numbers differ between sources?
Two labels exist for the same molecule and they give slightly different figures. Mounjaro, labelled for type 2 diabetes, states approximately 5 days. Zepbound, labelled for weight management, states approximately 5 to 6 days in patients with overweight or obesity. Nothing about the drug changed. The labelled populations differ, and body composition is one of the factors that moves pharmacokinetic estimates.
Run through the five half-life rule, that one-day difference matters more than it looks: 25 days on the Mounjaro figure against 25 to 30 days on the Zepbound range. Neither is wrong. They describe different groups of people.
What does a half-life not tell you?
It does not separate the two receptor actions. The GIP and GLP-1 effects of tirzepatide arrive on one molecule and one clearance curve, but how much each arm contributes to the clinical result in humans is still being investigated, and the half-life is silent on that.
It also does not tell you how long gastrointestinal effects, appetite changes or glucose lowering persist. Those depend on receptor signalling and on how the body has adapted over weeks of exposure, and a plasma decay curve captures neither. Repeated use also builds toward a steady level that this single-dose table does not model.
Can you run the numbers yourself?
The estimator applies the same decay arithmetic to any half-life, starting amount and time you enter. It opens with Tirzepatide's published value loaded. Type another figure to see how sensitive the result is to it.
Published value: Approximately 5 days (Subcutaneous) · Mounjaro label, DailyMed · Compound profile
Show the math
What are the limits of this estimate?
Everything above is a single-compartment approximation: one pool of drug, falling by the same fraction in every interval. Real elimination varies with kidney and liver function, body composition, formulation and route, and a published figure describes only the route and the people it was measured in. Many compounds also show a fast distribution phase before the slower elimination the table describes.
A half-life is not a dosing schedule. Labelled intervals come from clinical trials that measured outcomes and tolerability, and nothing on this page suggests when to take, repeat or stop anything. Whether Tirzepatide is out of your system for drug-testing purposes is a different question again. Tests often look for metabolites rather than the parent compound, and the answer depends on the assay, its sensitivity and the sample type, none of which a plasma half-life captures.
FAQ.
Is tirzepatide's half-life different from semaglutide's?
Yes, a little. The Mounjaro label gives approximately 5 days and the Ozempic label gives approximately 1 week for semaglutide. Both reach those figures through albumin-binding fatty-acid chains, and both are measured in days rather than hours.
Why does Zepbound list a different half-life from Mounjaro?
Same molecule, different labelled populations. Zepbound's approximately 5 to 6 days is stated for patients with overweight or obesity, while Mounjaro's approximately 5 days comes from its own labelled population. Pharmacokinetic estimates shift with the people they were measured in.
Does the label half-life apply to compounded tirzepatide?
It cannot be assumed to. The label values were measured with the approved product. Compounded or research-grade material sold outside the regulated supply chain is not FDA-approved, and nothing guarantees that its identity, purity or formulation match what the label studied.
For what the evidence on Tirzepatide actually shows, read the Tirzepatide profile. For approval and regulatory position, see is Tirzepatide legal. The half-life reference lists every sourced value side by side, including the compounds where a number circulates online with no reliable human data behind it.